Navigation Links
Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test
Date:5/1/2008

he IL1B gene is among the first gene activated when the body encounters a challenge of almost any type, ranging from bacterial infections to bad cholesterol. IL-1beta initiates a complex cascade of related immune responses. Interleukin Genetics' approach, started over fifteen years ago, is to study variations in regulatory, or on/off switch, regions for these first mover genes and then link them to biological events and risk of inflammatory disease.

Dr. Kenneth Kornman, Chief Scientific Officer at Interleukin Genetics and an author on the paper explained the practical utility of the IL1B genetic information. "We use a simple cheek swab to collect an individual's DNA. Our technologists perform the genetic analysis in our CLIA certified laboratory. A report is generated about an individual's risk for excess inflammation and cardiovascular disease. The privacy-ensured report is sent directly to the individual, who then has access to physicians and genetic counselors to discuss results."

These peer-reviewed results build on prior studies which showed that three gene variations inherited together from a parent, called a haplotype, functioned together to control regulation of the gene producing IL-1beta. In this study, four specific IL1B haplotype pairs, one from each parent, representing just over half of the study population, were associated with higher tissue levels of IL-1beta levels, and two of those haplotype pairs were also associated with increased blood CRP levels. CRP is an inflammatory chemical that is well-established as an independent marker of risk for heart disease.

Interleukin Genetics' Heart Health Genetic Test is available to consumers in the U.S. and Canada under the Gensona(R) brand and marketed by Alticor Inc. The Gensona(R) Heart Health Genetic Test employs a number of single nucleotide polymorphisms (genetic sequence variations called SNPs) to identify specific genetic patterns in the Interleukin 1 genes. These genetic patterns
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
2. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
3. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Video: New Research Discovers Independent Brain Networks Control Human Walking
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...v. 20 Soligenix, Inc. (O...), formerly known as DOR BioPharma, Inc., a late-s...t has formed a consortium to develop thermostable ...acting vaccines. Soligenix received a $9.4 million...Infectious Diseases (NIAID), a division of the Nat...
(Date:11/19/2009)... In response to an ever-increasing...l medicines, Operation Pangea II, involving 24 cou...Health Organization,s International Medical Produc...ight the dangers of buying medicines online. ,,...ies of arrests and the seizure of thousands of pot...
(Date:11/19/2009)..., Nov. 19 Alexza Pharmac...at its corporate presentation will be webcast live...Conference on Wednesday, December 2, 2009 at 9:00 ...st from The New York Palace Hotel in New York and ...ent and CEO. ,, To access the live presentati...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Medicines Top Source of Kids Poisonings 53612 1Medicines Top Source of Kids Poisonings 53612 2Medicines Top Source of Kids Poisonings 53612 3Medicines Top Source of Kids Poisonings 53612 4Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 53608 1Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 53608 2Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 53608 3VivaGel 28R 29 Demonstrates Anti HIV and Herpes Activity Following Human Administration 53604 1VivaGel 28R 29 Demonstrates Anti HIV and Herpes Activity Following Human Administration 53604 2
...wswire-FirstCall/ - Alfacell Corporation,(Nasdaq: ...the International,Journal of Oncology (2007; Vol. ...stantially decreases reactive oxygen intermediates...The observed antioxidant activity,of ONCONASE may ...ls and,mechanistic synergism with other anti-cance...
...V Therapeutics,Inc. (Nasdaq: CVTX ) announced tod...l update session on anti-arrhythmia data from the ...ntation at the European Society,of Cardiology (ESC...om,September 1-5, 2007. A clinical trial update s... Anti-anginal Agent with Electrophysiologic Proper...
Other Medicine Technology:Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007 2CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007 3
(Date:11/20/2009).... 20 Following a recall by Unileve...from sale Shedd,s Country Crock ® Side Dishes...Crock ® Side Dishes DELUXE Four Cheese Pasta ...following code dates and UPCs are affected: ,, ...heddar Broccoli Rice 21 oz, UPC 027400218316, Best...
(Date:11/20/2009)...PRNewswire-USNewswire/ -- The American Dental Asso...dministration (FDA) to establish appropriate class...iting concern about the safety of whitening produc... of professional consultation or examination by a ... of chemically based tooth whitening or bleaching ...
(Date:11/20/2009)...., Nov. 20 Samuel Gladd...ine what it means to be "happy" during the holiday...cialty in family counseling and chair of the Depar...dding says research shows that it is the pressure ...epression during the holidays. ,, That,s why he...
(Date:11/20/2009)...ne November 20 in the Journal of the National Can... hopes that often appear in news coverage of cance...th the media and journals to help alleviate the pr...n Woloshin, M.D., M.S., of Center for Medicine and...olicy and Clinical Practice in New Hampshire, and ...
(Date:11/20/2009)...ber 20, 2009Emergency medical service (EMS) provid...00 cardiac arrests each year. Only 5 to 10 percen.... Better quality cardiopulmonary resuscitation (C...ssociated with better patient outcome. The Resusc...linical research network to study prehospital trea...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...ch 5 Peregrine Pharmaceuticals, Inc. (Nasdaq: P...ancial results for the third quarter of fiscal yea... host a conference call and webcast to discuss the... 2009 and will review recent operating highlights....
...eives EU and US Approvals for Intravenous Formulat...l Temozolomide Sachet Presentation , , KENILWORTH...: SGP ) today announced that the European Commis...emozolomide is marketed as TEMODAL(R) in the EU an...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) tod...l year 2008 financial results after the NASDAQ Glo...at same afternoon, Jack Lief, Arena,s President an.... Eastern Time (2:00 p.m. Pacific Time) to discuss...
...., March 5 Smith & Nephew Inc,s Advanced Woun...y announced the U.S. launch of its next Negative P...SYS (TM) GO, designed to address the needs of cli...wound care. The U.S. Food and Drug Administration ...
...acquisition of NMHC drives GAAP earnings per share...4 2008, up from $6.5 million in Q4, 2007, ,...C Health Solutions Corp. ("SXC" or the "Company") ... in U.S. dollars unless otherwise indicated. , "20...
...e demand for a reliable, non-invasive, efficient a...s, lifestyles is boosting interest in bone growth ...t is however still small, as clinicians have felt ... research papers to substantiate the efficacy of t...
Other Medicine News:Health News:Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 2Health News:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 2Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 3Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 4Health News:Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 2Health News:According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators 3
Blue Line® Uncuffed Nasal Endotracheal Tubes (Ivory) Magill
Blue Line® Cuffed Cut-to-Length Oral/Nasal Endotracheal Tubes (clear PVC) Murphy
Uncuffed Nasoral Murphy
Super Safety Magill Cuffed Pediatric ET
Medicine Products: